INT201129

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 1.09
Pain Relevance 0.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (QRFPR) signal transducer activity (QRFPR)
Anatomy Link Frequency
capsules 1
internal 1
QRFPR (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 8 90.32 High High
headache 28 85.60 High High
pruritus 8 5.00 Very Low Very Low Very Low
Pain 5 5.00 Very Low Very Low Very Low
abdominal pain 4 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Malaria 103 98.64 Very High Very High Very High
Obesity 21 98.20 Very High Very High Very High
Headache 28 85.60 High High
Dizziness 41 83.36 Quite High
Arrhythmias 2 Under Development 16 79.52 Quite High
Vomiting 34 79.44 Quite High
Otitis Media 4 78.68 Quite High
Diarrhoea 12 77.68 Quite High
Disease 14 53.12 Quite High
Toxicity 28 33.80 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These sorts of studies do not tell researchers anything about the efficacy of the drug in treating malaria, but the results are absolutely essential before trials can be done that do test efficacy in people with malaria. 126 healthy volunteers were recruited into the study, and each received capsules containing a different dosage of either AQ-13 or CQ.
AQ-13 Binding (dosage) of in capsules associated with malaria
1) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Abstract Doc Link PMC1764434 Disease Relevance 0.65 Pain Relevance 0.09
Because the major metabolite of AQ-13 (mono-N-dealkylated AQ-13) is not active against CQ-resistant parasites, this adjustment was based on the AUC?
AQ-13 Binding (metabolite) of
2) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0.05
Quantitation was based on the peak:area ratios for AQ-13, CQ, and their metabolites in relation to the internal standard [26].


AQ-13 Binding (ratios) of in internal
3) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.08 Pain Relevance 0
Based on age, sex, race, weight, BMI, and the baseline QTc interval, there were no significant differences between volunteers randomized to AQ-13 versus CQ (Table 1).
AQ-13 Binding (randomized) of associated with obesity
4) Confidence 0.11 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.26 Pain Relevance 0
Quite a few made specific mention of anti-malarial drugs, either providing a description or their actual name; when shown samples of SP and AS-AQ they recognized them and could say they were for malaria - either treatment or prevention.
AS-AQ Binding (recognized) of associated with malaria
5) Confidence 0.00 Published 2010 Journal Malar J Section Body Doc Link PMC2817700 Disease Relevance 0.10 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox